Jane Street Group, LLC Celyad Oncology Sa Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 17, 2022	SELL	$1.72 - $4.08 $19,129 - $45,377	-11,122 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$3.56 - $5.0 $39,594 - $55,610	11,122 New	11,122 $44,000
Q1 2020 May 15, 2020	SELL	$4.18 - $12.42 $45,102 - $134,011	-10,790 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$8.46 - $12.74 $91,283 - $137,464	10,790 New	10,790 $117,000
Q2 2018 Aug 15, 2018	SELL	$26.05 - $35.15 $438,056 - $591,082	-16,816 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$34.1 - $47.52 $360,164 - $501,906	10,562 Added 168.88%	16,816 $586,000
Q4 2017 Feb 15, 2018	BUY	$35.81 - $64.0 $223,955 - $400,256	6,254	6,254 $260,000

Ticker CYAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,594,000
Market Cap $11.7M
Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.